Avalyn Pharma (AVLN) Stock Price, News & Analysis

Company Overview

Avalyn Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review. Avalyn is headquartered in the United States and conducts its work in collaboration with clinical, research and development partners. Information about additional commercial operations and geographic markets is limited because the company remains focused on clinical development rather than marketed products.

Key Stats

• Today's Range: $23.08 to $25.27
• 50-Day Range: $24.80 to $39.25
• 52-Week Range: $23.08 to $40.17
• Volume: 316,295 shs
• Average Volume: 317,442 shs
• Market Capitalization: $1.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Moderate Buy

Avalyn Pharma Stock Analysis - MarketRank™

Avalyn Pharma scored higher than 48% of companies evaluated by MarketBeat, and ranked 527th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Avalyn Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Avalyn Pharma has a consensus price target of $60.00, representing about 148.6% upside from its current price of $24.14.

Amount of Analyst Coverage

Avalyn Pharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avalyn Pharma are expected to grow in the coming year, from ($3.86) to ($2.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avalyn Pharma is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avalyn Pharma is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.68% of the float of Avalyn Pharma has been sold short.

Short Interest Ratio / Days to Cover

Avalyn Pharma has a short interest ratio ("days to cover") of 8.52.

Change versus previous month

Short interest in Avalyn Pharma has recently increased by 20.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avalyn Pharma does not currently pay a dividend.

Dividend Growth

Avalyn Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.66

News Sentiment

Avalyn Pharma has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Avalyn Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 3 people have added Avalyn Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avalyn Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

Avalyn Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AVLN
• CIK: 1540171
• Web: www.avalynpharma.com
• Phone: (206) 707-0340
• Fax: N/A
• Employees: 55
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Avalyn Pharma: $60.00
• High Price Target: $80.00
• Low Price Target: $51.00
• Potential Upside/Downside: +156.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 33.12
• Quick Ratio: 33.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 44,330,000
• Free Float: N/A
• Market Cap: $1.04 billion
• Optionable: N/A
• Beta: N/A